Nobelpharma
Specialty pharmaceutical company focused on bringing therapies and medical devices for unmet medical needs, particularly rare diseases. Strategy emphasizes in‑licensing and acquisition of externally developed candidates, prioritizing patient- and clinician‑driven development themes, concentrating on late‑stage clinical development and regulatory submissions, and partnering for commercialization and distribution in domestic and international markets. The company also provides medical affairs, patient support services, and pursues lifecycle management and drug‑repurposing activities.
Industries
Nr. of Employees
large (251-1000)
Nobelpharma
Products
Topical mTOR‑inhibitor formulation for facial angiofibromas in tuberous sclerosis
Topically applied mTOR‑inhibitor gel developed and launched for treatment of facial skin lesions associated with tuberous sclerosis complex; obtained regulatory approvals in multiple regions.
Oral therapy for Wilson disease (marketed in select territories)
Oral therapy indicated for Wilson disease that has been registered and marketed in selected international territories.
Topical mTOR‑inhibitor formulation for facial angiofibromas in tuberous sclerosis
Topically applied mTOR‑inhibitor gel developed and launched for treatment of facial skin lesions associated with tuberous sclerosis complex; obtained regulatory approvals in multiple regions.
Oral therapy for Wilson disease (marketed in select territories)
Oral therapy indicated for Wilson disease that has been registered and marketed in selected international territories.
Services
Creation and dissemination of disease information, educational materials and medically led scientific support for healthcare professionals and patients.
Web‑based guidance and referrals explaining public subsidy systems and social support programs to help patients access treatment.
Negotiation and management of licensing‑in deals, commercial partnerships and exclusive distribution agreements for medical devices and pharmaceutical products.
Creation and dissemination of disease information, educational materials and medically led scientific support for healthcare professionals and patients.
Web‑based guidance and referrals explaining public subsidy systems and social support programs to help patients access treatment.
Negotiation and management of licensing‑in deals, commercial partnerships and exclusive distribution agreements for medical devices and pharmaceutical products.
Expertise Areas
- Rare‑disease drug development
- In‑licensing and external candidate evaluation
- Late‑stage clinical development and trial management
- Drug repositioning and lifecycle management
Key Technologies
- Topical formulation development
- Drug repurposing and indication‑expansion strategies
- Late‑phase clinical development and trial design
- Regulatory dossier preparation for multi‑region submissions
News & Updates
Announcement of an exclusive distribution agreement with a medical laser manufacturer (news release).
Received US regulatory approval (March 2022) and launched a topical mTOR‑inhibitor gel for treatment of facial lesions associated with tuberous sclerosis (August 2022).
Obtained marketing authorizations in China (March 2023), the EU (May 2023) and the UK (September 2023) with subsequent regional launches.
Company‑reported cumulative approvals including multiple new drug approvals, additional indication approvals and at least one medical device approval since founding.
Announcement of an exclusive distribution agreement with a medical laser manufacturer (news release).
Received US regulatory approval (March 2022) and launched a topical mTOR‑inhibitor gel for treatment of facial lesions associated with tuberous sclerosis (August 2022).
Obtained marketing authorizations in China (March 2023), the EU (May 2023) and the UK (September 2023) with subsequent regional launches.
Company‑reported cumulative approvals including multiple new drug approvals, additional indication approvals and at least one medical device approval since founding.